Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
400 CHF | +388.82% |
|
-.--% | -.--% |
Jun. 13 | High-risk health workers can get routine Ebola vaccine, Gavi says | RE |
Jun. 13 | AbbVie inks immune disorder drug licensing deal with China's FutureGen | RE |
Sales 2024 * | 64.18B 57.18B | Sales 2025 * | 68.68B 61.19B | Capitalization | 328B 292B |
---|---|---|---|---|---|
Net income 2024 * | 19.51B 17.38B | Net income 2025 * | 22.25B 19.82B | EV / Sales 2024 * | 5.4 x |
Net Debt 2024 * | 18.6B 16.57B | Net Debt 2025 * | 7.28B 6.49B | EV / Sales 2025 * | 4.88 x |
P/E ratio 2024 * |
16.7
x | P/E ratio 2025 * |
14.5
x | Employees | - |
Yield 2024 * |
2.39% | Yield 2025 * |
2.53% | Free-Float | 70.77% |
Latest transcript on Merck & Co., Inc.
![Extreme 72.85](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
Director of Finance/CFO | 55 | 89-12-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 67 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.45% | 791B | |
+40.45% | 630B | |
+9.25% | 298B | |
+17.25% | 246B | |
+0.41% | 225B | |
+10.22% | 218B | |
+4.51% | 160B | |
-6.27% | 156B | |
-2.33% | 116B |
- Stock Market
- Equities
- MRK Stock
- MRK Stock